Projecting 18.9m EBITDA for FY21, and not quite reaching 100m ARR target by end of FY21 (91.7m)
Regardless, if we look ahead to FY23 with projected EBITDA of $63.3m (EPS of 0.05) due to flat cost growth but sustained receipt growth, and apply a 30x PE we have a $1.50 sp, which discounted back 3 years to present at 10% gives intrinsic value of circa $1.10.
Thatd put us on a current ARR multiple of 17x which would be much more in line with the line of best fit seen above based on revenue growth rate. Given the uncertainty over ability to execute on such an extreme inflection point in earnings, I wouldn't think such a multiple would be justifiable just yet.
- Forums
- ASX - By Stock
- LVT
- New Coverage by MST Access...
New Coverage by MST Access..., page-3
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LVT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.474M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
LVT (ASX) Chart |
Day chart unavailable